BioNTech Covid-19 Vaccine: Ugur Sahin tests are being run on the variant (Representational)
Highlights
- "Highly likely" its vaccine works against mutated strain, BioNTech said
- Could provide a new vaccine in six weeks, co-founder said
- Mutated strain first reported in Britain
The co-founder of BioNTech said Tuesday it was "highly likely" that its vaccine against the coronavirus works against the mutated strain detected in Britain, but it could also adapt the vaccine if necessary in six weeks.
"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin.
But if needed, "in principle the beauty of the messenger technology is that we can directly start to engineer a vaccine which completely mimics this new mutation -- we could be able to provide a new vaccine technically within six weeks."
Sahin said the variant detected in Britain has nine mutations, rather than just one as is usually common.
Nevertheless, he voiced confidence that the vaccine developed with Pfizer would be efficient because it "contains more than 1,000 amino acids, and only nine of them have changed, so that means 99 percent of the protein is still the same".
He said tests are being run on the variant, with results expected in two weeks.
"We have scientific confidence that the vaccine might protect but we will only know it if the experiment is done... we will publish the data as soon as possible," he added.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)